Hydroxybenzamide Hsp90 Inhibitors for Selective Cancer Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer lack effective targeting of Hsp90, a key chaperone protein involved in cancer cell survival and proliferation, due to its ubiquity and elevated activity in both normal and cancer cells, leading to non-specific cytotoxicity and resistance in signaling pathway redundancy.
Innovation Solution
Development of novel compounds with specific Hsp90 inhibitory activity that modulate the protein's function, potentially reducing cancer cell survival and proliferation by targeting key client proteins involved in signal transduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Hsp90 is targeted for inhibition, then cancer cell survival and proliferation are reduced, but normal cells are also affected due to ubiquitous expression
Solution Approach 1:
The patent applies local quality by designing inhibitors with selective affinity for Hsp90 in the context of cancer cell multichaperone complexes. The compounds preferentially bind to Hsp90 when it is part of activated complexes in cancer cells, while showing reduced activity against Hsp90 in normal cells, thereby achieving localized selective toxicity.
Solution Approach 2:
The patent utilizes parameter changes by exploiting differences in Hsp90 ATPase activity between cancer and normal cells. Cancer cells exhibit elevated ATPase activity, and the inhibitors are designed to target this hyperactive state, converting the harmful elevated activity into a selective vulnerability that can be exploited therapeutically.
2Reliability
If Hsp90 inhibitors are used to treat cancer, then oncogenic proteins are degraded, but resistance develops due to signaling pathway redundancy
Solution Approach 1:
The patent applies universality by designing Hsp90 inhibitors that can disrupt multiple signaling pathways simultaneously. Since Hsp90 supports numerous client proteins involved in different cancer-related pathways, inhibiting Hsp90 creates a multi-functional blockade that is harder for cancer cells to overcome through single-pathway compensation.
Solution Approach 2:
The patent converts the harmful redundancy of signaling pathways into a benefit by targeting Hsp90, which is essential for the function of multiple client proteins across different pathways. The very redundancy that normally allows resistance becomes a vulnerability when Hsp90 is inhibited, as multiple critical pathways are simultaneously disrupted.
3Measurement precision
If GA is used to inhibit Hsp90, then binding affinity is higher for tumour cells, but non-specific binding and off-target effects occur
Solution Approach 1:
The patent applies local quality by modifying the geldanamycin structure to enhance selective binding to Hsp90 in cancer cells while reducing off-target interactions. The structural modifications create compounds that maintain high affinity for the target in the cancer cell context but exhibit reduced binding to off-target proteins, thereby improving therapeutic specificity.
Solution Approach 2:
The patent uses composite material principles by creating hybrid molecules that combine the geldanamycin core with additional functional groups or moieties that enhance selectivity. These composite structures maintain the beneficial Hsp90 binding properties of geldanamycin while adding features that reduce non-specific binding and off-target effects.
Data Source
AI summary
The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group -(O)n-R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbylamino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur. The compounds have activity as Hsp90 inhibitors.